The analytical impact of extracellular vesicles PSA on different commercial total PSA measurement methods
Biochemia medica · 2026
DOI: 10.11613/bm.2026.010703 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biochemia medica, 2026. Verfasst von Ana Moreno und 9 weiteren Autor:innen. Beteiligte Einrichtung: Service of Biochemistry, Clínica Universidad de Navarra, Pamplona, Spain. Hauptthemen laut MEDLINE: Prostate-Specific Antigen, Extracellular Vesicles, Prostatic Neoplasms. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Introduction
Prostate-specific antigen (PSA) can circulate bound to extracellular vesicles (EVs) and its measurement (ev-PSA) can be useful in prostate cancer. Although not designed with that purpose, total PSA assays react with ev-PSA. We evaluated the analytical performance of several total PSA assays in ev-PSA quantification and the impact of ev-PSA on total PSA measurement. Materials and methods: Extracellular vesicles were isolated from 83 serum samples from prostate cancer patients by size exclusion chromatography or ultracentrifugation. PSA was quantified in serum, EVs, International Standard for PSA 17/100 from the World Health Organization (WHO IS 17/100) and exosomes from lymph node carcinoma of the prostate (LNCaP) cell line, using commercial immunoassays (Elecsys, Atellica, Immulite, Liaison and Kryptor).
Results
Nanoparticle tracking analysis showed that the WHO IS 17/100 contains significantly less EVs than serum (P < 0.001). The sensitivity to detect ev-PSA followed this order: Elecsys ~ Atellica > Immulite > Liaison > Kryptor. Ev-PSA could be detected in all serum samples with Elecsys and Atellica, but not with Immulite (87.8%), Liaison (58.5%) or Kryptor (48.8%). Bland-Altman analysis showed a proportional bias in ev-PSA quantification between Elecsys and other methods. Addition of ev-PSA to serum samples caused a proportional bias in PSA measurement between Elecsys and Immulite methods, with a relationship (r2 = 0.99; P < 0.001) between ev-PSA and the difference in total PSA concentration between both methods.
Conclusions
While ev-PSA can be measured using commercial kits, notable differences exist between methods, which could lead to potential discrepancies in serum total PSA results across various assays.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Service of Biochemistry, Clínica Universidad de Navarra, Pamplona, Spain.
- Laboratory of circulating biomarkers in cancer, Cancer Center Clínica Universidad de Navarra, Pamplona, Spain.
- Clinical Biochemistry Department, Vall d'Hebron University Hospital, Barcelona, Spain.
- Clinical Biochemistry, drug delivery and therapy Research Group, Vall d'Hebrón Research Institute (VHIR), Barcelona, Spain.
- Department of Urology, Clínica Universidad De Navarra, Pamplona, Spain.
- Department of Oncology, Clínica Universidad de Navarra, Pamplona, Spain.
Zitieren
APA
Moreno, A., Sandúa, A., Ferrer-Costa, R., Jacobs-Cacha, C., Varo, N., Ancizu-Marckert, J., Robles, J. E., Pérez Gracia, J. L., Alegre, E., & González, Á. (2026). The analytical impact of extracellular vesicles PSA on different commercial total PSA measurement methods. Biochemia medica. https://doi.org/10.11613/bm.2026.010703
Vancouver
Moreno A, Sandúa A, Ferrer-Costa R, Jacobs-Cacha C, Varo N, Ancizu-Marckert J, et al. The analytical impact of extracellular vesicles PSA on different commercial total PSA measurement methods. Biochemia medica. 2026. doi:10.11613/bm.2026.010703
BibTeX
@article{Moreno2026,
author = {Moreno, Ana and Sandúa, Amaia and Ferrer-Costa, Roser and Jacobs-Cacha, Conxita and Varo, Nerea and Ancizu-Marckert, Javier and Robles, Jose Enrique and Pérez Gracia, Jose Luis and Alegre, Estibaliz and González, Álvaro},
title = {The analytical impact of extracellular vesicles PSA on different commercial total PSA measurement methods},
journal = {Biochemia medica},
year = {2026},
doi = {10.11613/bm.2026.010703}
}
EUVIMED